Journal: Scientific Reports
Article Title: Pharmacological activation of BK channels protects against LPS-induced pneumonia
doi: 10.1038/s41598-025-08902-6
Figure Lengend Snippet: Pharmacological BK channel activation protects mice against LPS-induced pneumonia. LPS infection ( i.t. , 10 mg/kg) increased BALF total cell ( a , k ) and neutrophil counts ( b , l ), and BALF CCL-2 ( c , n ), MIP-1α ( o ) and CXCL-10 ( p ) concentrations, lung injury scores ( d , e ), and cytosolic ROS production by BALF cells ( f , m ). Two doses of the BK activator NS1619 or NS19504 ( i.t. , 0.66 mg/kg), given at 0 and 24 h improved all measured markers of acute lung injury. In contrast, mitochondrial ROS production ( g ), BALF total protein levels ( h , q ), quasi-static lung compliance ( i , r ), and body weight loss ( j , s ) were not affected by NS1619 treatment. Control mice received equimolar drug vehicle injections. n = 3–10 mice per group; individual experimental data points are depicted within each bar; bars depict mean ± SEM; *p < 0.05; IF—intensity of fluorescence; A.U.—arbitrary units; scale bar: 650 µm.
Article Snippet: Separate groups also received i.t. injections of the BK channel activator NS1619 (0.66 mg/kg in 50 μl in sterile PBS; Millipore, Burlington, MA) or NS19504 (1.33 mg/kg in 50 μl in sterile PBS; Alomone labs, Israel), the BK channel blocker Paxilline (1.33 mg/kg in 50 μl in sterile PBS; Alomone labs, Israel), or equimolar vehicle controls, at times 0 and 24 h. We then quantified the degree of lung injury at 48 h. This model resulted in a moderate degree of lung injury with potential for recovery (< 3% mortality), representing a clinically relevant infection.
Techniques: Activation Assay, Infection, Control, Fluorescence